• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Lasa Share Price

    Lasa Supergenerics Share PriceLasa Supergenerics

    Small Cap 4.1k Result
    ₹26.9
    -0.1 (-0.37%)
    As on 22 September, 2023 | 23:00 BSE: 540702 NSE: LASAISIN: INE670X01014

    Lasa Supergenerics Performance

    Day Range

    • Low 26.3
    • High 27.3
    26.9

    52 Week Range

    • Low 17.1
    • High 43
    26.9
    • Open Price26.6
    • Previous Close27
    • Volume33546

    Start SIP in Lasa Supergenerics

    Start SIP

    Lasa Supergenerics Share Price

    • Over 1 Month 10.7%
    • Over 3 Month 24.25%
    • Over 6 Month 24.25%
    • Over 1 Year -35.34%

    Lasa Supergenerics Key Statistics

    P/E Ratio -4.3
    PEG Ratio 0.1
    Market Cap Cr 135
    Price to Book Ratio 1.1
    EPS -3.9
    Dividend 0
    Relative Strength Index 45.68
    Money Flow Index 13.46
    MACD Signal 0.83
    Average True Range 1.66

    Lasa Supergenerics Investment Rating

    • Master Rating:

    • Lasa Supergenerics has an operating revenue of Rs. 131.25 Cr. on a trailing 12-month basis. An annual revenue de-growth of -4% needs improvement, Pre-tax margin of -33% needs improvement, ROE of -32% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 5% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 24 which is a POOR score indicating inconsistency in earnings, a RS Rating of 34 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 45 indicates it belongs to a fair industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Lasa Supergenerics Financials
    IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 313532342951
    Operating Expenses Qtr Cr 273134343740
    Operating Profit Qtr Cr 44-20-811
    Depreciation Qtr Cr 343333
    Interest Qtr Cr 000100
    Tax Qtr Cr 6-4001-1
    Net Profit Qtr Cr -5-15-5-7-1212
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 131137
    Operating Expenses Annual Cr 136121
    Operating Profit Annual in Cr -716
    Depreciation Cr 1314
    Interest Annual Cr 40
    Tax Annual Cr -4-1
    Net Profit Annual Cr -39-5
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 10
    Cash from Investing Activity Annual Cr -3
    Cash from Financing Annual Activity Cr 0
    Net Cash Flow Annual Cr 7
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 118149
    Fixed Assets Annual Cr 124127
    Total Non Current Assets Annual Cr 125127
    Total Current Assets Annual Cr 3972
    Total Assets Annual Cr 164199
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 2437
    ROE Annual % -33-4
    ROCE Annual % -151
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % -411
    IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr
    Operating Expenses Qtr Cr
    Operating Profit Qtr Cr
    Depreciation Qtr Cr
    Interest Qtr Cr
    Tax Qtr Cr
    Net Profit Qtr Cr
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr
    Operating Expenses Annual Cr
    Operating Profit Annual in Cr
    Depreciation Cr
    Interest Annual Cr
    Tax Annual Cr
    Net Profit Annual Cr
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr
    Cash from Investing Activity Annual Cr
    Cash from Financing Annual Activity Cr
    Net Cash Flow Annual Cr
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr
    Fixed Assets Annual Cr
    Total Non Current Assets Annual Cr
    Total Current Assets Annual Cr
    Total Assets Annual Cr
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs
    ROE Annual %
    ROCE Annual %
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin %

    Lasa Supergenerics Technicals

    EMA & SMA

    Current Price
    ₹26.9
    -0.1 (-0.37%)
    • Bullish Moving Average
    • ___
    • 6
    • Bearish Moving Average
    • ___
    • 10
    • 20 Day
    • ₹27.95
    • 50 Day
    • ₹26.57
    • 100 Day
    • ₹25.71
    • 200 Day
    • ₹27.46
    • 20 Day
    • ₹29
    • 50 Day
    • ₹25.85
    • 100 Day
    • ₹24.52
    • 200 Day
    • ₹25.64

    Lasa Supergenerics Resistance and Support

    PIVOT
    ₹26.84
    Resistance
    First Resistance ₹27.37
    Second Resistance ₹27.84
    Third Resistance ₹28.37
    RSI 45.68
    MFI 13.46
    MACD Single Line 0.83
    MACD 0.31
    Support
    First Resistance ₹26.37
    Second Resistance ₹25.84
    Third Resistance ₹25.37

    Lasa Supergenerics Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 41,760 4,176,000 100
    Week 54,036 5,403,625 100
    1 Month 289,581 15,828,518 54.66
    6 Month 150,351 8,780,507 58.4

    Lasa Supergenerics Result Highlights

    Lasa Supergenerics Synopsis

    NSE-Medical-Ethical Drugs

    Lasa Supergenerics is involved in the business activities of Manufacture of veterinary preparations. Company’s Total Operating Revenue is Rs. 129.57 Cr. and Equity Capital is Rs. 50.10 Cr. for the Year ended 31/03/2023. Lasa Supergenerics Ltd. is a Public Limited Listed company incorporated on 11/11/2016 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24233MH2016PLC274202 and registration number is 274202.
    Market Cap 134
    Sales 131
    Shares in Float 2.30
    No of funds 1
    Yield 1.14
    Book Value 1.14
    U/D Vol ratio 2.6
    LTDebt / Equity
    Alpha -0.09
    Beta 0.94

    Lasa Supergenerics

    Owner NameJun-23Mar-23Jan-23Dec-22
    Promoters 53.65%53.65%53.65%43.78%
    Mutual Funds
    Insurance Companies
    Foreign Portfolio Investors
    Financial Institutions/ Banks
    Individual Investors 33.87%33.87%31.29%38.13%
    Others 12.48%12.48%15.06%18.09%

    Lasa Supergenerics Management

    Name Designation
    Dr. Omkar Pravin Herlekar Chairman & Managing Director
    Mr. Shivanand G Hegde Whole Time Director
    Mr. Hardesh Raja Tolani Independent Director
    Ms. Ekta Avtar Gurnasinghani Independent Director
    Mr. Ajay Hareshlal Sukhwani Independent Director
    Ms. Manali Roop Bhagtani Independent Director

    Lasa Supergenerics Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Lasa Supergenerics Corporate Action

    Date Purpose Remarks
    2023-08-14 Quarterly Results
    2023-06-07 Audited Results (Revised) per share(2.5%)Final Dividend
    2023-02-14 Quarterly Results
    2022-11-14 Quarterly Results
    2022-08-08 Quarterly Results

    Lasa Supergenerics MF Shareholding

    Name Amount(cr)
    Motilal Oswal S&P BSE Healthcare ETF 8
    • Company Name
    • CMP
    • Chg(%)
    • Company Name
    • CMP
    • Chg(%)

    Lasa Supergenerics FAQs

    What is Share Price of Lasa Supergenerics ?

    Lasa Supergenerics share price is ₹26 As on 22 September, 2023 | 22:46

    What is the Market Cap of Lasa Supergenerics ?

    The Market Cap of Lasa Supergenerics is ₹134.8 Cr As on 22 September, 2023 | 22:46

    What is the P/E ratio of Lasa Supergenerics ?

    The P/E ratio of Lasa Supergenerics is -4.3 As on 22 September, 2023 | 22:46

    What is the PB ratio of Lasa Supergenerics ?

    The PB ratio of Lasa Supergenerics is 1.1 As on 22 September, 2023 | 22:46

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Enter Mobile Number

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.